Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Shares Outstanding (Diluted Average) (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $103.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 10.7% to $103.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103.2 million through Dec 2025, up 10.7% year-over-year, with the annual reading at $103.2 million for FY2025, 10.7% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $103.2 million at Day One Biopharmaceuticals, roughly flat from $103.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $103.4 million in Q3 2025, with the low at $58.4 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $82.5 million, with a median of $83.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 25.81% in 2023, then rose 10.7% in 2025.
  • Over 4 years, Shares Outstanding (Diluted Average) stood at $65.5 million in 2022, then increased by 21.85% to $79.8 million in 2023, then rose by 16.87% to $93.2 million in 2024, then rose by 10.7% to $103.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $103.2 million, $103.4 million, and $103.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.